Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4779366 | 0.89 | P2RX7 (0.45) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL4727470 | 0.85 | NPC1 (0.60) | NPC1RAB9AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL10090449 | 0.78 | OPRM1 (0.51) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL27810817 | 0.78 | NPC1 (0.58) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL10882236 | 0.77 | BCHE (0.48) | NPC1RAB9AALDH1A1KMT2AMEN1 | |
| SCHEMBL2845619 | 0.76 | NPC1 (0.49) | NPC1RAB9AALDH1A1SMN1; SMN2HTT | |
| SCHEMBL4993840 | 0.76 | CNR1 (0.51) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL27789231 | 0.75 | ALDH1A1 (0.57) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL14559619 | 0.74 | NPC1 (0.67) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL4996564 | 0.74 | SMN1; SMN2 (0.48) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071625-B2 | E.g., [(1-(2-aminoacetyl)-4-{N-[(3-fluoro-2-methylphenyl)methyl]carbamoyl}(4-piperidyl))methoxy]-N-(4-ethylphenyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071625-B2 | E.g., [(1-(2-aminoacetyl)-4-{N-[(3-fluoro-2-methylphenyl)methyl]carbamoyl}(4-piperidyl))methoxy]-N-(4-ethylphenyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071625-B2 | E.g., [(1-(2-aminoacetyl)-4-{N-[(3-fluoro-2-methylphenyl)methyl]carbamoyl}(4-piperidyl))methoxy]-N-(4-ethylphenyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction | CYTOKINETICS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20080194633-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194633-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194633-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008016676-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008016676-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194633-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | NPC1 4684/4885RAB9A 2065/4885ALDH1A1 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.